Diabetic patients take drugs to avoid lower sugar problems, especially people with type 2 diabetes. A new clinical trial says that a diabetes test drug that is going to be invented has chances for reducing the Alzheimer’s dementia risk.
To Diabetics, New Drug Will Lower Risk Of Alzheimer’s Dementia
Usually, dementia is having the most common disease specified with Alzheimer’s. Dementia follows the general decline where mental abilities will interfere with severe risks in daily human life. Commonly, to decrease the cause of dementia, “Memantine” is used according to the severity of symptoms.
Through many collaborations and clinical tests, the diabetic shrug shows the findings of decreasing the risk of dementia. Researchers are doing extra research by examining the drug capabilities by its course change among people’s brains to stop the development of Alzheimer’s Dementia.
These drug trials are done under ISAP (the impact of semaglutide in Amyloid Positivity) followed by the 88 volunteers who have dementia. These 88 participants initially had their PET scan (positron emission tomography) to check the amyloid protein level present in their brains.
Scientists believe that if the amyloid protein level in the brain is high, there will be an increased risk of dementia. So, they named this study as a “preclinical” study under dementia risk with a long stage.
Researchers say that “people with type 2 diabetes are having less risk of brain plaque and they are blessed with a better cognitive score with Alzheimer’s disease.”
The drug named “dipeptidyl peptidase four and DPP-4” is prescribed as an inhibitor for type 2 diabetic patients for helping them to decrease lower blood sugar in their body because people who are linked with Alzheimer’s disease are suffering from high blood sugar levels and an increase of amyloid protein in the brain.
Dr. Ivan Koychev is the lead researcher of this study; he says that “though Dementia is the fatal form of Alzheimer’s disease, this became the 6th leading death cause among people of the United States” and “among old American citizens, dementia became 5th leading cause in America.”
Diabetic people will get easily affected with Dementia in Alzheimer’s disease because diabetes is the major risk factor that causes brain damage by blocking the blood flow. These affect changes in the brain and cause vascular dementia and Alzheimer’s disease.
Many drugs are found nowadays to decrease the dementia risk among diabetic patients. However, those drugs are still not considered because they are currently not supported by the proper evidence and clinical trial history.
Researchers now started their clinical trial treatments by prescribing a PET scan with a must protocol for determining amyloid and tau protein in the brain to estimate brain inflammation. People with type 2 diabetes are suggested to take a placebo tablet daily for one long year without negligence. During this period, initial scans will be performed to check the inflammation levels in the brain.
Researchers say that “type 2 diabetic people must be careful and follow correct diet and prescribed medicines regularly without fail” because some diabetic people might get affected with heart disease and heart strokes. In contrast, findings say that some diabetic patients also suffer from an increase in dementia risk.
The study strongly warned diabetic patients not to use some specific drugs because they might increase the risk of Alzheimer’s Dementia, such as Antipsychotics, Antidepressants, Antiepileptic drugs, Anti-Parkinson drugs, and Antimuscarinic.
A recent clinical trial study says that a drug named “gliptin” is used for patients with Alzheimer’s disease because gliptins contain hallmark Alzheimer’s protein and amyloid protein at lower levels. After continuing the trials, results show a better growth score among patients according to the tests conducted regarding thinking and memory.